Carotid Artery Disease

First patient enrolled in surveillance study of carotid artery stenting system

Published in Medical Letter on the CDC and FDA, October 31st, 2004

Cordis Endovascular, a division of Cordis Corp., a Johnson & Johnson company, announced that a patient in Newport Beach, California, is the first to enroll in the company's surveillance study of its carotid artery stenting system for treatment of patients with carotid artery disease at high-risk for adverse events from carotid endarterectomy.

"Through this surveillance study we seek to corroborate findings of the landmark SAPPHIRE study, the only randomized clinical trial conducted to validate the potential of carotid artery stent placement in high surgical-risk patients," said Subbarao Myla, MD, medical director, cardiovascular research and vascular interventions, Hoag...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry